It has been proposed that dysregulation of the fuel sensing enzyme AMPK could be both a pathogenic factor for type 2 diabetes and other disorders associated with the metabolic syndrome and a target for their therapy. Nutrient excess reduces AMPK activity and causes insulin resistance (IR) in incubated rat EDL muscle (high glucose or leucine), cultured HepG2 cells (high glucose) and muscle and liver of rats infused with glucose (high glucose and insulin). In all three models, we have found that these changes are associated with a decrease in SIRT1 and activation of mTORC1, two other fuel sensing molecules that have been linked to the metabolic syndrome. Where examined, decreased AMPK activity appeared to be the initial event and activation of AMPK prevented all of these changes from occurring, including the IR. In separate studies, others have shown that AMPK can activate SIRT1 and we have found that SIRT1 can activate AMPK, suggesting the existence of a SIRT1/AMPK cycle in which these molecules jointly govern many key enzymes and transcriptional regulators. Upon this background, studies will be performed with the following specific aims: (1) To examine at a mechanistic level how AMPK, SIRT1 and mTORC1 functionally interact with each other in incubated muscle and cultured HepG2 cells. In doing so, we will also test the hypothesis, suggested by our preliminary data, that the initial effect of a nutrient excess is to downregulate AMPK by causing it to interact with a protein phosphatase. (2) To determine in the same models how dysregulation of the three molecules leads to IR and under what conditions the IR is associated with inflammation, oxidative and ER stress and mitochondrial abnormalities. In the process, we will evaluate AMPK, SIRT1 and mTORC as targets both for preventing and treating IR using metabolic, pharmacological and genetic approaches and (3) To test whether the mechanisms defined in vitro are operative in muscle, liver and adipose tissue in vivo using the glucose- infused rat and genetically modified mice as models. Collectively, these studies will provide novel information about fundamental mechanisms by which nutrient excess leads to IR in mammalian tissues. They are especially timely since therapies that activate AMPK and SIRT1 are presently being used or are undergoing trials for disease prevention and treatment in humans.

Public Health Relevance

The metabolic syndrome underlies such disorders as type 2 diabetes, coronary heart disease, hypertension and Alzheimer's disease and probably contributes to accelerated aging. We have identified three fuel sensing and signaling molecules, AMPK, SIRT1, and mTORC1 whose dysregulation could contribute to these disorders. The proposed studies will explore at a molecular level how these molecules interact with each other and in turn, how their activation (or inhibition) could diminish insulin resistance, a hallmark of the metabolic syndrome, caused by nutrient excess.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK067509-08
Application #
8512707
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Laughlin, Maren R
Project Start
2004-04-01
Project End
2015-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
8
Fiscal Year
2013
Total Cost
$321,635
Indirect Cost
$102,694
Name
Boston Medical Center
Department
Type
DUNS #
005492160
City
Boston
State
MA
Country
United States
Zip Code
02118
Weikel, Karen A; Ruderman, Neil B; Cacicedo, José M (2016) Unraveling the actions of AMP-activated protein kinase in metabolic diseases: Systemic to molecular insights. Metabolism 65:634-45
Weikel, Karen A; Cacicedo, José M; Ruderman, Neil B et al. (2016) Knockdown of GSK3? increases basal autophagy and AMPK signalling in nutrient-laden human aortic endothelial cells. Biosci Rep 36:
Coughlan, Kimberly A; Valentine, Rudy J; Sudit, Bella S et al. (2016) PKD1 Inhibits AMPK?2 through Phosphorylation of Serine 491 and Impairs Insulin Signaling in Skeletal Muscle Cells. J Biol Chem 291:5664-75
Brandon, Amanda E; Tid-Ang, Jennifer; Wright, Lauren E et al. (2015) Overexpression of SIRT1 in rat skeletal muscle does not alter glucose induced insulin resistance. PLoS One 10:e0121959
Coughlan, Kimberly A; Balon, Thomas W; Valentine, Rudy J et al. (2015) Nutrient Excess and AMPK Downregulation in Incubated Skeletal Muscle and Muscle of Glucose Infused Rats. PLoS One 10:e0127388
Doménech, Elena; Maestre, Carolina; Esteban-Martínez, Lorena et al. (2015) AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol 17:1304-16
Martínez de Morentin, Pablo B; Lage, Ricardo; González-García, Ismael et al. (2015) Pregnancy induces resistance to the anorectic effect of hypothalamic malonyl-CoA and the thermogenic effect of hypothalamic AMPK inhibition in female rats. Endocrinology 156:947-60
Coughlan, Kimberly A; Valentine, Rudy J; Ruderman, Neil B et al. (2014) AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 7:241-53
Valentine, Rudy J; Coughlan, Kimberly A; Ruderman, Neil B et al. (2014) Insulin inhibits AMPK activity and phosphorylates AMPK Ser???/??¹ through Akt in hepatocytes, myotubes and incubated rat skeletal muscle. Arch Biochem Biophys 562:62-9
Ruderman, Neil B; Carling, David; Prentki, Marc et al. (2013) AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123:2764-72

Showing the most recent 10 out of 36 publications